## WNK-IN-11

Cat. No.:	HY-112094			
CAS No.:	2123489-30-3			
Molecular Formula:	$C_{21}H_{21}Cl_2N_5OS$			
Molecular Weight:	462			
Target:	Ser/Thr Protease			
Pathway:	Metabolic Enzyme/Protease			
Storage:	Powder	-20°C	3 years	
		4°C	2 years	
	In solvent	-80°C	2 years	
		-20°C	1 year	

®

MedChemExpress

### SOLVENT & SOLUBILITY

In Vitro	DMSO : 150 mg/mL (324.68 mM; Need ultrasonic)					
Preparing Stock Solutions		Solvent Mass Concentration	1 mg	5 mg	10 mg	
	1 mM	2.1645 mL	10.8225 mL	21.6450 mL		
		5 mM	0.4329 mL	2.1645 mL	4.3290 mL	
		10 mM	0.2165 mL	1.0823 mL	2.1645 mL	
	Please refer to the so	lubility information to select the app	propriate solvent.			
In Vivo	<ol> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution</li> </ol>					

BIOLOGICAL ACTIVITY				
Description	WNK-IN-11 is an allosteric With-No-Lysine (WNK) kinase inhibitor, with an IC <sub>50</sub> of 4 nM for WNK1.			
IC <sub>50</sub> & Target	IC50: 4 nM (WNK1) <sup>[1]</sup> .			
In Vitro	WNK-IN-11 (compound 11) shows IC <sub>50</sub> <2 μM in the cellular OSR1 phosphorylation assay with reasonable aqueous solubility, albeit with still rather high microsomal clearance. WNK-IN-11 shows ATP noncompetitive inhibition. When tested against a panel of 440 human kinases at 10 μM concentration, 2500-fold above enzyme IC <sub>50</sub> value, WNK-IN-11 shows excellent selectivity with only a few significant off-target kinase inhibitions, most notably BTK and feline encephalitis virus-related (FER) kinase, neither of which are implicated for blood pressure regulation. This excellent selectivity profile is consistent with the predicted allosteric binding mode outside the highly conserved ATP-pocket <sup>[1]</sup> .			

# Product Data Sheet

Y N. \_CI

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **CUSTOMER VALIDATION**

• Nat Commun. 2021 Jul 27;12(1):4546.

See more customer validations on www.MedChemExpress.com

#### REFERENCES

[1]. Yamada K, et al. Optimization of Allosteric With-No-Lysine (WNK) Kinase Inhibitors and Efficacy in Rodent Hypertension Models. J Med Chem. 2017 Aug 24;60(16):7099-7107.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA